Caregivers should watch for nausea, vomiting, diarrhea, reduced appetite, weight loss, and patch-site reactions while someone takes rivastigmine. They should act promptly on dehydration, bleeding, seizures, urinary problems, a severe allergic reaction, a slow heart rate, or accidental use of two patches. Rivastigmine is a medication available in patch and capsule forms. Its common digestive side effects are dose-related, so symptoms after a dose increase deserve close attention.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Monitor eating, fluids, and weight
- Symptoms that need prompt medical advice
- Prevent patch errors and recognize skin allergy
- Who may be more vulnerable?
- Restart carefully after an interruption
- What trial percentages can—and cannot—tell you
Monitor eating, fluids, and weight
Nausea, vomiting, diarrhea, reduced appetite, and weight loss are common concerns. Prolonged vomiting or diarrhea can cause dehydration and serious outcomes, according to the Sandoz FDA-approved label on DailyMed. Caregivers can track meals, drinks, vomiting, diarrhea, and body weight.
Contact the prescribing clinician if symptoms persist, fluid intake falls, or weight begins dropping. In a 1,195-person trial, 8% of those using the 9.5-mg/24-hour patch lost at least 7% of their starting weight. The placebo rate was 6%. That two-percentage-point difference cannot predict one person's experience, but it supports regular weight checks.
Symptoms that need prompt medical advice
MedlinePlus advises seeking prompt medical help for several potentially serious reactions: These symptoms should not wait for the next routine appointment. When contacting a clinician, report when the problem started, the current dose, recent dose changes, and whether any doses or patches were missed.
The full warning list appears in the NIH MedlinePlus rivastigmine guidance. Keep the medication package or an updated medicine list available when asking for help.
- Black or bloody stools
- Bloody vomit or vomit resembling coffee grounds
- Seizures
- Painful or difficult urination
- A severe allergic reaction
Prevent patch errors and recognize skin allergy
Only one rivastigmine patch should be worn at a time. Wearing multiple patches—often because the previous patch was not removed—has caused serious reactions, hospitalization, and, rarely, death, according to the FDA-approved patch label on DailyMed.
Use a repeatable patch routine: The patch can also cause allergic contact dermatitis, a skin allergy caused by contact with the medication or patch. Discontinue the patch and contact the clinician if redness, swelling, bumps, or blisters spread beyond its outline or fail to improve substantially within 48 hours after removal.
- Locate and remove the old patch before opening another.
- Confirm that only one patch remains on the skin.
- Record each removal and application.
- Include patch checks during caregiver handoffs.
Who may be more vulnerable?
People weighing under 50 kg, or about 110 pounds, may be more vulnerable to toxicity such as excessive nausea and vomiting. The label recommends careful dose increases, close monitoring, and possible dose reduction. Rivastigmine may also slow the heart rate.
This risk matters particularly for people with sick-sinus syndrome or another disorder affecting electrical conduction above the heart's ventricles. Make sure the prescribing clinician knows about a low body weight or diagnosed conduction disorder. Ask what changes should trigger a call and whether the person needs specific heart-rate monitoring.
Restart carefully after an interruption
An interruption longer than three days changes how rivastigmine should be restarted. Resuming the previous dose without stepping down can increase the risk of severe vomiting. The Sandoz FDA-approved label says to restart at the lowest patch dose or at 1.5 mg twice daily for capsules, followed by another gradual dose increase.
Contact the prescribing clinician before giving the next dose if the interruption exceeded three days. Count missed days carefully rather than estimating. Record the last confirmed dose or patch date so another caregiver or clinician can verify the interruption.
What trial percentages can—and cannot—tell you
Clinical-trial percentages offer useful context, but they are not personal forecasts. The FDA-approved label cautions that adverse-event rates from different trials cannot be compared directly and may not match everyday care.
A simple dated record can reveal changes that a single observation misses. Track doses, patch placement, digestive symptoms, meals, fluids, and weight, then bring that record to the prescribing clinician when symptoms appear or the dose changes.
